Skip to main content
Top
Published in: Pituitary 3/2011

01-09-2011

Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population

Author: Pedro Weslley Rosario

Published in: Pituitary | Issue 3/2011

Login to get access

Abstract

The objective of this study was to evaluate the frequency of acromegaly in adults with diabetes mellitus (DM) or glucose intolerance (GI) and to estimate its prevalence in the general population. A total of 2,270 patients with DM or GI and age from 20 to 70 years were studied. Patients with known pituitary disease and pregnant women were excluded. Serum IGF-1 was measured in all subjects and, if elevated, a new measurement was obtained together with the measurement of GH in the oral glucose tolerance test (OGTT). Patients with persistently elevated IGF-1 and inadequate suppression of GH were submitted to magnetic resonance imaging (MRI). Acromegaly was not suspected by the assistant physician in any of the patients. Six patients had persistently elevated IGF-1 and inadequate suppression of GH in the OGTT (without other conditions associated with GH or IGF-1 elevation). Pituitary adenoma was detected by MRI in three patients, and two subjects presented an acromegalic phenotype. Two patients were submitted to transsphenoidal surgery, with immunohistochemistry confirming immunoreactivity for GH. Another patient was treated with octreotide LAR which resulted in the normalization of IGF-1 and GH. Considering a prevalence of DM or GI of 20% in adults and the occurrence of these co-morbidities in 55% of patients with acromegaly, the frequency of 3/2,270 found in this study permits to estimate 480 cases/1,000,000 adults. The present results suggest that the prevalence of acromegaly is underestimated and further studies are needed to evaluate the cost-effectiveness of biochemical screening in certain groups of patients.
Literature
2.
go back to reference Buurman H, Saeger W (2006) Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 154:753–758PubMedCrossRef Buurman H, Saeger W (2006) Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 154:753–758PubMedCrossRef
3.
go back to reference Tomita T, Gates E (1999) Pituitary adenomas and granular cell tumors. Incidence, cell type, and location of tumor in 100 pituitary glands at autopsy. Am J Clin Pathol 111:817–825PubMed Tomita T, Gates E (1999) Pituitary adenomas and granular cell tumors. Incidence, cell type, and location of tumor in 100 pituitary glands at autopsy. Am J Clin Pathol 111:817–825PubMed
4.
go back to reference Coulon G, Fellmann D, Arbez-Gindre F, Pageaut G (1983) Latent pituitary adenoma. Autopsy study. Sem Hop 59:2747–2750PubMed Coulon G, Fellmann D, Arbez-Gindre F, Pageaut G (1983) Latent pituitary adenoma. Autopsy study. Sem Hop 59:2747–2750PubMed
5.
go back to reference Kim JH, Seo JS, Lee BW, Lee SY, Jeon SH, Lee KB (2007) The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases. J Korean Med Sci 22(Suppl):S61–S65PubMedCrossRef Kim JH, Seo JS, Lee BW, Lee SY, Jeon SH, Lee KB (2007) The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases. J Korean Med Sci 22(Suppl):S61–S65PubMedCrossRef
6.
go back to reference Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769–4775PubMedCrossRef Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769–4775PubMedCrossRef
7.
go back to reference Cannavò S, Ferraù F, Ragonese M, Curtò L, Torre ML, Magistri M, Marchese A, Alibrandi A, Trimarchi F (2010) Increased prevalence of acromegaly in a highly polluted área. Eur J Endocrinol 163:509–513PubMedCrossRef Cannavò S, Ferraù F, Ragonese M, Curtò L, Torre ML, Magistri M, Marchese A, Alibrandi A, Trimarchi F (2010) Increased prevalence of acromegaly in a highly polluted área. Eur J Endocrinol 163:509–513PubMedCrossRef
8.
go back to reference Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69:432–435CrossRef Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69:432–435CrossRef
9.
go back to reference Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006; acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72:203–208CrossRef Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006; acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72:203–208CrossRef
10.
go back to reference Psaras T, Milian M, Hattermann V, Freiman T, Gallwitz B, Honegger J (2010) Demographic factors and the presence of comorbidities do not promote early detection of Cushing’s disease and acromegaly. Exp Clin Endocrinol Diabetes. doi:10.1055/s-0030-1263104 Psaras T, Milian M, Hattermann V, Freiman T, Gallwitz B, Honegger J (2010) Demographic factors and the presence of comorbidities do not promote early detection of Cushing’s disease and acromegaly. Exp Clin Endocrinol Diabetes. doi:10.​1055/​s-0030-1263104
11.
go back to reference Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152PubMedCrossRef Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152PubMedCrossRef
12.
go back to reference Molitch ME (1992) Clinical manifestations of acromegaly. Endocrinol Metab Clin N Am 21:597–614 Molitch ME (1992) Clinical manifestations of acromegaly. Endocrinol Metab Clin N Am 21:597–614
13.
go back to reference Biering H, Knappe G, Gerl H (2000) Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Aust 27:27–31CrossRef Biering H, Knappe G, Gerl H (2000) Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Aust 27:27–31CrossRef
14.
go back to reference Colao A, Baldelli R, Marzullo P (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199PubMedCrossRef Colao A, Baldelli R, Marzullo P (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199PubMedCrossRef
15.
go back to reference Ezzat S, Forster MJ, Berchtold P (1994) Acromegaly: clinical and biochemical features in 500 patients. Medicine 73:233–240PubMedCrossRef Ezzat S, Forster MJ, Berchtold P (1994) Acromegaly: clinical and biochemical features in 500 patients. Medicine 73:233–240PubMedCrossRef
16.
go back to reference Mercado M, Espinosa de los Monteros AL, Sosa E (2004) Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62:293–299PubMedCrossRef Mercado M, Espinosa de los Monteros AL, Sosa E (2004) Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62:293–299PubMedCrossRef
17.
go back to reference Mestron A, Webb SM, Astorga R (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 151:439–446PubMedCrossRef Mestron A, Webb SM, Astorga R (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 151:439–446PubMedCrossRef
18.
go back to reference Tanimoto K, Hizuka N, Fukuda I, Takano K, Hanafusa T (2008) The influence of age on the GH-IGF1 axis in patients with acromegaly. Eur J Endocrinol 159:375–379PubMedCrossRef Tanimoto K, Hizuka N, Fukuda I, Takano K, Hanafusa T (2008) The influence of age on the GH-IGF1 axis in patients with acromegaly. Eur J Endocrinol 159:375–379PubMedCrossRef
19.
go back to reference Donangelo I, Une K, Gadelha M (2003) Diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metab 47:331–346CrossRef Donangelo I, Une K, Gadelha M (2003) Diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metab 47:331–346CrossRef
20.
go back to reference Malerbi D, Franco LJ (1992) The Brazilian Cooperative Group on the Study of Diabetes Prevalence. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30–69 years. Diabetes Care 15:1509–1516PubMedCrossRef Malerbi D, Franco LJ (1992) The Brazilian Cooperative Group on the Study of Diabetes Prevalence. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30–69 years. Diabetes Care 15:1509–1516PubMedCrossRef
21.
go back to reference Torquato MT, Montenegro RN Jr, Viana LAL (2003) Prevalence of diabetes mellitus and impaired glucose tolerance in the urban population aged 30–69 years in Ribeirão Preto (São Paulo), Brazil. São Paulo Med J 121:224–230PubMed Torquato MT, Montenegro RN Jr, Viana LAL (2003) Prevalence of diabetes mellitus and impaired glucose tolerance in the urban population aged 30–69 years in Ribeirão Preto (São Paulo), Brazil. São Paulo Med J 121:224–230PubMed
23.
go back to reference American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(suppl 1):S62–S67CrossRef American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(suppl 1):S62–S67CrossRef
24.
go back to reference Rosario PW (2010) Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metab 54:477–481CrossRef Rosario PW (2010) Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metab 54:477–481CrossRef
25.
go back to reference Rosario PW, Furtado M (2008) Growth hormone after oral glucose overload: revision of reference values in normal subjects. Arq Bras Endocrinol Metab 52:1139–1144 Rosario PW, Furtado M (2008) Growth hormone after oral glucose overload: revision of reference values in normal subjects. Arq Bras Endocrinol Metab 52:1139–1144
26.
go back to reference Freda P (2004) Acromegaly—diagnostic pitfalls. The Endocrinologist 14:277–287CrossRef Freda P (2004) Acromegaly—diagnostic pitfalls. The Endocrinologist 14:277–287CrossRef
27.
go back to reference Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71:166–170CrossRef Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71:166–170CrossRef
28.
go back to reference Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537–3542PubMedCrossRef Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537–3542PubMedCrossRef
29.
go back to reference Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN (2003) Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6:175–180PubMedCrossRef Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN (2003) Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6:175–180PubMedCrossRef
30.
go back to reference Doppman JL, Miller DL, Patronas NJ, Oldfield EH, Merriam GR, Frank SJ, Flack MR, Weintraub BD, Gorden P (1990) The diagnosis of acromegaly: value of inferior petrosal sinus sampling. AJR Am J Roentgenol 154:1075–1077PubMed Doppman JL, Miller DL, Patronas NJ, Oldfield EH, Merriam GR, Frank SJ, Flack MR, Weintraub BD, Gorden P (1990) The diagnosis of acromegaly: value of inferior petrosal sinus sampling. AJR Am J Roentgenol 154:1075–1077PubMed
31.
go back to reference Daud S, Hamrahian AH, Weil RJ, Hamaty M, Prayson RA, Olansky L (2010) Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration? Pituitary doi:10.1007/s11102-009-0205-z Daud S, Hamrahian AH, Weil RJ, Hamaty M, Prayson RA, Olansky L (2010) Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration? Pituitary doi:10.​1007/​s11102-009-0205-z
32.
go back to reference Lonser RR, Kindzelski BA, Mehta GU, Jane JA Jr, Oldfield EH (2010) Acromegaly without imaging evidence of pituitary adenoma. J Clin Endocrinol Metab. doi:10.1210/jc.2010-0570 Lonser RR, Kindzelski BA, Mehta GU, Jane JA Jr, Oldfield EH (2010) Acromegaly without imaging evidence of pituitary adenoma. J Clin Endocrinol Metab. doi:10.​1210/​jc.​2010-0570
33.
go back to reference Lim DJ, Kwon HS, Cho JH, Kim SH, Choi YH, Yoon KH, Cha BY, Lee KW, Son HY, Kang SK (2007) Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia. Endocr J 54:537–541PubMedCrossRef Lim DJ, Kwon HS, Cho JH, Kim SH, Choi YH, Yoon KH, Cha BY, Lee KW, Son HY, Kang SK (2007) Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia. Endocr J 54:537–541PubMedCrossRef
34.
go back to reference Arihara Z, Sakurai K, Yamada S, Murakami O, Takahashi K (2008) Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus. Tohoku J Exp Med 216:325–329PubMedCrossRef Arihara Z, Sakurai K, Yamada S, Murakami O, Takahashi K (2008) Acromegaly with normal IGF-1 levels probably due to poorly controlled diabetes mellitus. Tohoku J Exp Med 216:325–329PubMedCrossRef
35.
Metadata
Title
Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population
Author
Pedro Weslley Rosario
Publication date
01-09-2011
Publisher
Springer US
Published in
Pituitary / Issue 3/2011
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-010-0281-0

Other articles of this Issue 3/2011

Pituitary 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.